Effects of schistosomiasis on susceptibility to HIV-1 infection and HIV-1 viral load at HIV-1 seroconversion: A nested case-control study. by Downs, Jennifer A et al.
RESEARCH ARTICLE
Effects of schistosomiasis on susceptibility to
HIV-1 infection and HIV-1 viral load at HIV-1
seroconversion: A nested case-control study
Jennifer A. Downs1,2*, Kathryn M. Dupnik1, Govert J. van Dam3, Mark Urassa4,
Peter Lutonja4, Dieuwke Kornelis3, Claudia J. de Dood5, Pytsje Hoekstra3,
Chifundo Kanjala4, Raphael Isingo4, Robert N. Peck1,2, Myung Hee Lee1, Paul L. A.
M. Corstjens5, Jim Todd6, John M. Changalucha4, Warren D. Johnson, Jr.1, Daniel
W. Fitzgerald1
1 Center for Global Health, Department of Medicine, Weill Cornell Medicine, New York, New York, United
States of America, 2 Department of Medicine, Bugando Medical Centre, Mwanza, Tanzania, 3 Department
of Parasitology, Leiden University Medical Center, Leiden, the Netherlands, 4 National Institute for Medical
Research, Mwanza, Tanzania, 5 Department of Molecular Cell Biology, Leiden University Medical Center,
Leiden, the Netherlands, 6 Department of Applied Biostatistics, London School of Hygiene and Tropical
Medicine, London, United Kingdom
* jna2002@med.cornell.edu
Abstract
Background
Schistosomiasis affects 218 million people worldwide, with most infections in Africa. Preva-
lence studies suggest that people with chronic schistosomiasis may have higher risk of HIV-
1 acquisition and impaired ability to control HIV-1 replication once infected. We hypothe-
sized that: (1) pre-existing schistosome infection may increase the odds of HIV-1 acquisition
and that the effects may differ between men and women, and (2) individuals with active
schistosome infection at the time of HIV-1 acquisition may have impaired immune control of
HIV-1, resulting in higher HIV-1 viral loads at HIV-1 seroconversion.
Methodology/Principal findings
We conducted a nested case-control study within a large population-based survey of
HIV-1 transmission in Tanzania. A population of adults from seven villages was tested
for HIV in 2007, 2010, and 2013 and dried blood spots were archived for future studies
with participants’ consent. Approximately 40% of this population has Schistosoma man-
soni infection, and 2% has S. haematobium. We tested for schistosome antigens in the
pre- and post-HIV-1-seroconversion blood spots of people who acquired HIV-1. We also
tested blood spots of matched controls who did not acquire HIV-1 and calculated the
odds that a person with schistosomiasis would become HIV-1-infected compared to
these matched controls. Analysis was stratified by gender. We compared 73 HIV-1 sero-
converters with 265 controls. Women with schistosome infections had a higher odds of
HIV-1 acquisition than those without (adjusted OR = 2.8 [1.2–6.6], p = 0.019). Schisto-
some-infected men did not have an increased odds of HIV-1 acquisition (adjusted OR =
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0.7 [0.3–1.8], p = 0.42). We additionally compared HIV-1 RNA levels in the post-serocon-
version blood spots in HIV-1 seroconverters with schistosomiasis versus those without
who became HIV-infected in 2010, before antiretroviral therapy was widely available in
the region. The median whole blood HIV-1 RNA level in the 15 HIV-1 seroconverters with
schistosome infection was significantly higher than in the 22 without schistosomiasis: 4.4
[3.9–4.6] log10 copies/mL versus 3.7 [3.2–4.3], p = 0.017.
Conclusions/Significance
We confirm, in an area with endemic S. mansoni, that pre-existing schistosome infection
increases odds of HIV-1 acquisition in women and raises HIV-1 viral load at the time of HIV-
1 seroconversion. This is the first study to demonstrate the effect of schistosome infection
on HIV-1 susceptibility and viral control, and to differentiate effects by gender. Validation
studies will be needed at additional sites.
Author summary
Schistosomiasis is a neglected tropical parasitic worm infection that affects 218 million
people worldwide, the majority of whom live in Africa. Studies have shown that women
with schistosomiasis tend to have higher rates of HIV infection, but until now no study
has followed people over time to determine whether schistosomiasis increases a person’s
risk of becoming HIV-infected. In this ongoing community study in rural Tanzania, we
identified 73 individuals who became HIV-infected during follow-up, and 265 control
individuals who were similar in age, sex, and location but who remained HIV-uninfected
during follow-up. We tested these individuals’ stored blood samples to determine whether
they had schistosome infection before they became HIV-infected. We found that women
who had schistosome infections had a 2.8-fold increased risk of becoming HIV-infected
compared to women without schistosome infections. We found no evidence of increased
HIV acquisition in men with schistosome infections. We also found that the concentra-
tion of HIV in the blood shortly after people became HIV-infected was higher in those
who had schistosome infections than in those who did not have schistosome infections.
Our study suggests that schistosomiasis may play a major role in HIV transmission and
disease progression in African countries.
Introduction
Schistosomiasis is a parasitic worm infection acquired by contact with contaminated fresh
water. Over 90% of the world’s 218 million schistosome infections occur in Africa [1]. Schis-
tosome worms live in the human host’s pelvic and gastrointestinal venules and daily lay
hundreds of eggs that migrate to the urogenital and gastrointestinal mucosa. These eggs
cause mucosal inflammation and physical breaches in the mucosa. These schistosome-
induced changes are postulated to alter host susceptibility and immune control of HIV-1
infection [2,3].
Three cross-sectional studies in Tanzania and Zimbabwe have demonstrated increased
prevalence of HIV infection in women with Schistosoma haematobium [4,5] or S. mansoni [6]
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infection. In our studies in Mwanza, Tanzania, women with S. haematobium infection were
four times more likely to be HIV-1-infected than women without schistosomiasis, and women
with S. mansoni were six times more likely [4,6]. These epidemiologic studies were conducted
in women because the eggs of S. haematobium and S. mansoni in the female genital tract cause
inflammation and ulceration and have been hypothesized to facilitate HIV-1 viral entry follow-
ing sexual exposure [7–9]. Genital lesions are less common in men [10,11].
Macaque studies suggest that S. mansoni infection may increase susceptibility to HIV infec-
tion and increase HIV-1 RNA viral load levels in those who become HIV-infected. Macaques
with and without pre-existing S. mansoni infection were rectally inoculated with progressively-
increasing doses of simian HIV (sHIV). Macaques with S. mansoni infection developed sys-
temic sHIV infection at a dose 17 times lower than macaques without schistosomiasis [12].
The investigators observed no difference in sHIV susceptibility when these experiments were
repeated using intravenous inoculation of sHIV rather than inoculation via the rectal mucosa
[13]. This implies that schistosome infection may alter mucosal integrity, thereby increasing
susceptibility to trans-mucosal HIV infection.
In addition, two studies have found that macaques with pre-existing S. mansoni infection
developed higher sHIV viral loads for the first 10 to 28 weeks post-sHIV inoculation than
macaques without schistosomiasis [12,14]. Again, this effect on viral load was only seen when
macaques were infected rectally and not when they were infected intravenously [13]. In
humans, HIV-1 viremia peaks 6–18 days after acute infection [15]. As host HIV-1 specific
immune responses develop, viremia is reduced to a point of equilibrium between host and
virus, leading to a stable viral load set-point within 6 weeks [15]. Set-points vary by several
orders of magnitude between individuals and are influenced by host genetics, host immune
factors, and viral genetics [16]. Elevated set-points lead to increased HIV-1 transmission and
more rapid progression to AIDS and death [17,18].
Our goal was to determine whether schistosome infection affects susceptibility to HIV-1
acquisition and HIV-1 viral load at the time of HIV-1 seroconversion. We therefore conducted
a nested case-control study within a large ongoing population-based survey of HIV-1 trans-
mission in northwest Tanzania. We analyzed dried blood spots that had been stored prospec-
tively to test our hypotheses that: (1) pre-existing schistosome infection may increase the
odds of HIV-1 acquisition and that the effects may differ between men and women, and (2)
individuals with active schistosome infection at the time of HIV-1 acquisition may have
impaired immune control of HIV-1, resulting in higher HIV-1 viral loads at the time of HIV-1
seroconversion.
Methods
Ethics statement
This project was approved by Bugando Medical Centre (Mwanza, Tanzania, BREC/001/04/2011),
the National Ethical Review Board (Dar es Salaam, Tanzania, NIMR/HQ/R8.a/Vol.IX/1313), and
Weill Cornell Medicine (New York, USA, 1108011883). Written informed consent was obtained
from study participants, and consent from parents of those aged 15 to 17 years with assent of the
minor was obtained. Study participants also provided consent for future testing of dried blood
spot samples in accordance with approved procedures of the Kisesa cohort study [19]. Dried
blood spot samples were stored anonymously and unlinked from personal identifiers.
Study area
Since 1994, the Kisesa observational HIV-1 cohort study has serially surveyed and HIV-tested
community members living in the Kisesa Ward in the Magu District of northwest Tanzania
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[20]. The Kisesa study area includes seven villages located near Lake Victoria. Consenting ado-
lescents and adults aged 15 and above are tested for HIV infection every 3 years. They receive
free voluntary HIV counseling and testing with same-day results and participate in structured
interviews. Dried blood spots are also archived for future studies with study participants’ con-
sent. This ongoing study is operated by the TAZAMA Project under the Tanzanian National
Institute for Medical Research in Mwanza.
The current study utilized data from archived dried blood spots collected from participants
in the Kisesa cohort during sero-surveys in 2007, 2010, and 2013. Sociodemographic data
from the same time points were also available. In this area of Tanzania, ~40% of adults have S.
mansoni infection and 2% have S. haematobium infection [6,21,22]. In our other studies, less
than one-fourth of adults in this region have reported receiving praziquantel treatment in the
past five years [6,22].
Study design
Study of HIV-1 susceptibility. To test our hypothesis that individuals with schistosome
infection were at higher risk of HIV-1 acquisition, we conducted a case-control study nested
within the Kisesa cohort. We identified HIV-1 seroconverters from two successive surveys
conducted by the cohort study: those whose dried blood spots tested negative for HIV in 2007
and positive for HIV-1 in 2010, and those whose dried blood spots tested negative for HIV in
2010 and positive for HIV-1 in 2013. HIV-1 seroconverters were selected randomly from
among all HIV-1 seroconverters identified during successive surveys. For each HIV-1 serocon-
verter, we sought four controls who also had dried blood spots available and were HIV-nega-
tive at the same two time points, and matched them to cases by gender, village, and age (within
5 years if age< 35, and within 10 years if 35). We compared proportions of schistosome
antigen CAA-positivity between cases and controls. Results were stratified by gender.
Study of HIV-1 viral loads at time of HIV-1 seroconversion. To test our hypothesis that
individuals with schistosome infection at the time of HIV-1 acquisition would have higher
viral loads at the time of HIV-1 seroconversion, we identified HIV-1 seroconverters who were
HIV-negative in 2007 and HIV-1-positive in 2010. We restricted our analysis to this time
point because in 2012 antiretroviral therapy became widely available in the region [23,24].
Because seroconverters had become HIV-1-infected during the three-year period since their
prior negative HIV test and because the viral load set-point is generally stable from 6 weeks
until at least 24 months post-infection and typically longer [25,26], we assumed that the HIV-1
RNA level measured would be reflective of the HIV-1 RNA viral load set-point in most HIV-1
seroconverters. We quantified schistosome circulating anodic antigen (CAA) in the dried
blood spots collected before and after HIV-1 seroconversion, and measured HIV-1 RNA levels
in the dried blood spots collected at the time the HIV-1 seroconversion was identified. We
compared HIV-1 viral loads between people with and without schistosome infection at the
time of HIV-1 acquisition.
Study definitions. We defined an individual as schistosome-infected at the time of HIV-1
seroconversion if the dried blood spots collected both before and after HIV-1 seroconversion
tested positive for schistosome CAA. We defined the viral load at the time of HIV-1 serocon-
version as the number of copies/mL of HIV-1 RNA in whole blood from the first dried blood
spot at which a participant was identified as HIV-1-sero-positive.
Laboratory testing
Specimens. Capillary blood was collected by finger prick directly onto the five sample
spots of a Whatman Protein Saver 903 card (GE Healthcare Bio-Sciences, Pennsylvania). Each
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sample spot contains ~80 μL of blood. Blood spot cards were dried out of direct sunlight and
then sealed in a gas-impermeable zip-bag with desiccant and humidity indicator. Dried blood
spots were tested for HIV at the National Institute for Medical Research laboratory in Mwanza
using the 4th-generation Vironostika Uni-Form Antigen/Antibody test (Organon Teknika, the
Netherlands) with Enzygnost Anti-HIV1/2 Plus (Dade Behring, Germany) for confirmation of
positives. All laboratory analysis was performed by technicians who were blinded to other
results.
CAA quantification. Circulating anodic antigen (CAA) is a glycosaminoglycan-like
carbohydrate regurgitated by adult schistosome worms into the host bloodstream [27,28].
CAA antigen levels are directly proportional to the worm burden in the host [29,30]. CAA
is a stable molecule, detectable in serum and dried blood spots, that does not differentiate
between schistosome species [21,29]. We quantified CAA in dried blood spots as previously
described [21]. Briefly, a 216 mm2 area of dried blood spot was cut from the card, eluted in
phosphate-buffered saline overnight, and concentrated using a 10 kDa concentration device
(Amicon Ultra–0.5mL Centrifugal Filters, Millipore). Immunochromatography, scanning
of lateral flow test strips, and calculation of CAA concentrations were performed at Leiden
University Medical Center with a lower limit of quantitation of the CAA assay of 2 pg/mL
(Leiden, the Netherlands).
Quantification of whole blood HIV-1 RNA. The Abbott system was used to quantify
whole blood HIV-1 RNA copies per mL in dried blood spots, as previously described [31–33].
This system requires one full dried blood spot (133 mm2, containing 80 μL blood), which was
placed application side inwards into a 2 mL microtube. 1.1 mL of Bulk Lysis Buffer GPR
(Abbott, Illinois) was added to the dried blood spot and vortexed. After room-temperature
incubation for one hour with intermittent vortexing, the lysate (800 μL) was placed into a new
tube. RNA was extracted from 600 μL of lysate using the mSample Preparation System and
quantified by m2000 Real-Time HIV-1 assay (Abbott, Illinois), per the manufacturer’s instruc-
tions. To ensure specimen quality, all samples were run with an internal positive control and
each PCR run included negative, low-positive, and high-positive m2000 controls, per the man-
ufacturer’s recommendations. An additional extraction positive control for all runs was a
dried blood spot replicate from the same HIV-1-positive sample.
The Abbott m2000 machine reports viral load results as copy numbers per mL of extracted
lysate. Whole blood viral load was calculated by multiplying the value obtained from the input
lysate by 10 (to account for the 80:800 dilution of whole blood in lysis buffer) [33]. The lower
limit for quantification by quantitative PCR is 400 copies/mL. Detectable viral load values
below 400 copies/mL were recorded as 399 copies/mL, and undetectable viral loads were
recorded as 1 copy/mL [31,32].
Statistical considerations
Data were analyzed using Stata/IC 14 (StataCorp, Texas, USA). Binary variables were
described as proportions and continuous variables were described as medians [interquartile
ranges]. Proportions were compared by Chi-square or Fisher’s exact test and medians by Wil-
coxon rank-sum test.
Analysis of HIV-1 susceptibility. We used univariable conditional logistic regression to
calculate odds ratios for subsequent HIV-1 acquisition among individuals with versus without
schistosome infection, while accounting for matching. Variables in the conditional logistic
regression models were chosen by a backward selection procedure that began with all variables
and used an elimination criteria of p>0.1. We pre-specified that we would analyze the data
stratified by gender due to postulated gender-specific mechanisms of HIV-1 susceptibility [2].
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Analysis of viral loads at HIV-1 seroconversion. To assess the relationship between the
logarithm of the HIV-1 RNA viral load at HIV-1 seroconversion and schistosomiasis, we used
a multivariable tobit regression analysis with a lower limit of log10 (399) to account for left-
censored data. To account for variance in the viral loads across villages, we used a random
effects tobit regression. The results from the tobit analysis are interpreted as the increased
log10 viral load in those with schistosomiasis, weighted by the proportion seen with a viral load
of 400 copies/ml or more. We compared all models using the likelihood ratio test.
Due to the limited and irreplaceable nature of dried blood spots, we tested only the mini-
mum number of samples required according to pre-specified power calculations at 5% signifi-
cance. We calculated that 74 HIV-1 seroconverters and four matched controls would provide
>80% power to detect an odds ratio of 3 for HIV-1 infection, stratified by gender. We calcu-
lated that viral load quantification in 37 HIV-1 seroconverters would provide 83% power to
detect a difference of 0.5 log10 HIV-1 RNA copies/mL in those with versus without schisto-
some infection. There was an insufficient number of HIV-1 seroconverters in 2010 to power
an analysis of viral loads stratified by gender.
Results
Study population and selection of dried blood spots
In 2010, 3,146 adults who were HIV-uninfected in 2007 were re-tested and 54 were found to
have HIV-1-seroconverted during the three-year interval. In 2013, 2,701 adults who had been
HIV-uninfected in 2010 were re-tested and 40 had newly HIV-1-seroconverted (Fig 1). We
obtained dried blood spots for schistosome testing from 37 of the 2010 seroconverters and 37
of the 2013 seroconverters who were randomly selected from among all HIV seroconverters.
One blood spot from a 2013 HIV-1 seroconverter was lost accidentally in the laboratory. Con-
trols were selected to match the HIV-1 seroconverters at each time point.
Study of HIV susceptibility
For the case-control study, we were able to identify 4 controls for 55 cases, 3 controls for 9
cases, and 2 controls for 9 cases, yielding a total of 73 HIV-1 seroconverters and 265 HIV-
uninfected controls. Cases and controls had a median age of 35 [interquartile range, 25–43]
years and 34 [interquartile range, 25–44] years, respectively. Women comprised 61% of cases
(45/73) and controls (162/265). Cases were included from all seven of the villages in the
TAZAMA project, with a range of 4 to 18 cases and their matched controls coming from each
village. Characteristics of HIV-1-infected cases and HIV-negative controls, stratified by gen-
der, are shown in Table 1.
In women, 20/45 HIV-1 seroconverters (44%) had schistosome infection at the time of
HIV-1 acquisition, compared to 48/162 female HIV-uninfected controls (30%). After control-
ling for marital status and painful urination, women with schistosome infections had a 2.8-fold
higher odds of incident HIV-1 infection than women without schistosome infections (OR = 2.8
[95% CI, 1.2–6.6], p = 0.019). In men, 8/28 HIV-1 seroconverters (29%) had schistosome infec-
tion at the time of HIV-1 acquisition, compared to 39/103 controls (38%), (OR = 0.7 [0.3–1.8],
p = 0.42 after controlling for marital status). These data are shown in Fig 2.
Study of whole blood viral load at HIV-1 seroconversion
For the study of HIV-1 RNA viral loads, we measured schistosome CAA in the dried blood
spots of the 37 individuals who were diagnosed with HIV-1 infection in 2010. There were 22
women and 15 men. Fifteen of these (41%) had schistosome infection. There were no
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significant differences in baseline characteristics between those with and without schistosome
infection. Study participants in both groups had had their last negative HIV test a median of
39 [interquartile range, 39–40] months before their first positive HIV test.
We observed a significantly higher median whole blood HIV-1 RNA level in the 15 HIV-1
seroconverters with schistosome infection than in the 22 without schistosomiasis: 4.4 [3.9–4.6]
log10 copies/mL versus 3.7 [3.2–4.3], p = 0.017 (Fig 3). On multivariable tobit regression by a
backward selection procedure with an elimination criteria of p>0.05, the best-fit model
included schistosome infection status and number of sexual partners in the past 12 months.
This yielded an adjusted log10 HIV-1 RNA difference of 0.62 (β = 0.62 [0.23–1.01], p = 0.003).
The HIV-1 RNA level was 0.9 log10 copies/mL higher in the 11 women with schistosomiasis
than the 11 women without (4.4 versus 3.5 log10 copies/mL, p = 0.02). The HIV-1 RNA level
was 0.6 log10 copies/mL higher in the 4 men with schistosomiasis than the 11 men without (4.5
versus 3.9, p = 0.24).
Only one individual had an HIV-1 RNA level that was greater than 5 log10 copies/mL, and
this person did not have schistosome infection. Two men had log10 HIV-1 RNA levels that
were< 400 copies/mL and both of them were schistosome-uninfected; when these two values
were removed from the analysis, the difference in median HIV-1 RNA levels remained signifi-
cant (4.4 versus 3.9 log10 copies/mL in those with versus without schistosomiasis, p = 0.039).
Fig 1. Flow diagram depicting identification of HIV-1 seroconverters and controls who remained HIV-
uninfected. The numbers of people tested in 2007, 2010, and 2013 in the Kisesa HIV-1 observational cohort
study are detailed above. Incident cases identified in 2010 and 2013 are indicated with red font. Dried blood
spots from 73 of these HIV-1 seroconverters were utilized in the current studies. We also analyzed dried blood
spots from 265 HIV-uninfected matched controls who were repeat tested but remained HIV-seronegative.
https://doi.org/10.1371/journal.pntd.0005968.g001
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Of the 22 women included in the viral load analysis, two had been pregnant in the past year.
Both women had delivered 5–6 months prior to dried blood spot collection, and the viral loads
measured in their dried blood spots were both> 4 log10 copies/mL.
Discussion
This study demonstrates that schistosome infection increases the susceptibility of women to HIV-
1 acquisition and increases the HIV-1 viral load at HIV-1 seroconversion in those who become
HIV-1-infected. Approximately 200 million schistosome-infected individuals live in African
countries with generalized HIV-1 epidemics, and ~6 million of these are HIV-1 co-infected
[1,34]. Our study suggests that interactions exist between HIV-1 and schistosomiasis that may
play a critical role in HIV-1 transmission and disease progression in African countries.
Our study, conducted in an area endemic for S. mansoni, urges consideration of a causal
relationship between S. mansoni infection and subsequent HIV-1 acquisition in women. Mul-
tiple studies already support the concept that parasite egg-induced damage to the urogenital
mucosa may be a risk factor for HIV acquisition in S. haematobium infection. Autopsy studies
suggest that S. mansoni eggs can also be found in the urogenital tract, particularly in heavily-
infected individuals, and that eggs are not exclusively localized in the gastrointestinal tract as
traditionally taught. In an autopsy series of individuals with mixed S. haematobium/S. mansoni
infections in Egypt, 55% of total body S. mansoni eggs were in the intestinal mucosa and 24%
were in the urogenital tract [35]. A case series in Tanzania showed that more than half of
women with biopsy-confirmed S. mansoni infection of the cervix and no S. haematobium ova
Table 1. Demographic and behavioral characteristics of HIV-1-infected cases and HIV-uninfected controls, by gender.
Characteristic
HIV-1-infected
women
(n = 45)
HIV-
uninfected
women
(n = 162)
p-value for
women
HIV-
1-infected
men
(n = 28)
HIV-
uninfected
men
(n = 103)
p-value for
men
Years of school attended 7 [7–7] 7 [7–7] 0.40 7 [7–7] 7 [6–7] 0.89
Marital status
Never married or cohabited
Monogamously married / cohabiting
Polygamously married / cohabiting
Widowed / separated / divorced
8 (18.6)
17 (37.8)
4 (9.3)
16 (37.2)
27 (17.3)
98 (62.8)
10 (6.4)
21 (13.5)
0.82
0.010
0.51
0.001
3 (10.7)
21 (75.0)
1 (3.6)
3 (10.7)
27 (26.7)
60 (59.4)
11 (10.9)
3 (3.0)
0.08
0.19
0.46
0.12
Occupation
Farming
Small business
Student
Other / none
34 (75.6)
6 (13.3)
2 (4.4)
3 (6.7)
125 (78.6)
9 (5.7)
14 (8.8)
14 (8.6)
0.84
0.10
0.53
1.0
24 (85.7)
0
1 (3.6)
3 (10.7)
85 (82.5)
1 (1.0)
12 (11.6)
5 (4.9)
0.78
1.0
0.30
0.37
Age in years at first sex 17 [15–18] 17 [15–19] 0.29 19 [15–21] 18 [17–21.5] 0.97
Number of lifetime sexual partners 3 [2–4] 2 [1–3] 0.005 6 [3–10] 5 [2–10] 0.30
Number of recent different sexual
partners**
1 [0–1] 1 [1–1] 0.018 1 [1–2] 1 [1–2] 0.69
Recent painful urination** 22 (51.1) 55 (35.3) 0.058 12 (42.9) 43 (42.6) 0.98
Recent genital discharge or ulcer** 15 (33.3) 25 (15.4) 0.007 4 (14.3) 13 (12.6) 0.81
Recent hospitalization** 6 (14.0) 19 (12.2) 0.76 1 (3.6) 5 (5.0) 0.76
Pregnant in the past three years** 20 (44.4) 79 (48.8) 0.61 — — —
Schistosome CAA infection 20 (44.4) 48 (29.6) 0.061 8 (28.6) 39 (37.9) 0.36
*Values shown are number (percent) or median [interquartile range] and are for available data. No variable was missing more than 3% of values.
**Time-dependent data were documented by the Kisesa observational HIV-1 cohort study at the time of the study participant’s HIV-1 diagnosis. Study
participants were asked to report on behavior or events during the prior 12 months. For pregnancy data, participants reported the date of last delivery.
https://doi.org/10.1371/journal.pntd.0005968.t001
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detected had visible lesions in the cervical tissue [8]. We therefore posit that S. mansoni has
urogenital mucosal effects, in addition to its known intestinal mucosal effects, that increase
women’s HIV-1 susceptibility. Plausible mechanisms include schistosome egg-induced physi-
cal breaches in genital mucosal tissue and recruitment of HIV-1-susceptible immune cells
[2,5,36]. Anal sex could also contribute to our findings, as macaque studies support the
hypothesis that S. mansoni-infected individuals likely have increased susceptibility to rectal
HIV exposure [12].
We found that schistosomiasis increases the odds of HIV-1 acquisition in women but not
in men. This strong gender effect may be due to differential effects of schistosome eggs in the
genital mucosa of women versus men. In autopsy studies of the gastrointestinal and genitouri-
nary organs in women with S. haematobium infection, the genital organs with the heaviest bur-
dens of eggs were the cervix, vagina, and uterus [11,37,38]. These genital organs were also the
most commonly affected organs in women with S. mansoni infection, with lower tissue egg
burdens in S. mansoni-infected than in S. haematobium-infected women [35,37]. Multiple
studies in men have demonstrated that the genital organs most affected by the eggs of both S.
haematobium and S. mansoni are the seminal vesicles and prostate [11,35,39]—internal organs
that are not exposed during sexual HIV-1 contact. This gender effect may explain why a prior
study from Uganda reported no increased odds of HIV-1 seroconversion in S. mansoni-
infected individuals [40]. The Uganda study had more men than women and did not examine
differential effects by gender. Further, schistosome infections were three times more prevalent
in men than in women (75% versus 21%). The study did find that history of anti-schistosome
treatment was protective against incident HIV-1 infection.
Fig 2. Prevalence of schistosome infection among HIV-1 seroconverters and matched controls, stratified
by gender. In women, 44% of HIV-1 seroconverters had schistosome infection, compared to 30% of controls
(p = 0.019). In men, 29% of HIV-1 seroconverters had schistosome infection, compared to 38% of controls
(p = 0.42). These differences were not detectable when cases and controls were analyzed without stratification by
gender.
https://doi.org/10.1371/journal.pntd.0005968.g002
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We also found that schistosomiasis at the time of HIV-1 infection led to a 0.7 log10
increase in viral load at the time of HIV-1 seroconversion. A sustained 0.7 log10 HIV-1 viral
load increase equates with an approximate doubling in infectivity among HIV-1-schisto-
some co-infected individuals and would be expected to accelerate time to symptomatic
AIDS or death by 2–3 years [41]. This finding of increased HIV-1 RNA viral load at sero-
conversion is supported by studies from humans and mice showing that schistosome-
induced immune alterations may impair the host’s ability to control viral replication. It is
also supported by a recent Cochrane review suggesting that treatment of helminth infec-
tions in HIV-helminth co-infected individuals may decrease the HIV-1 RNA viral load [42].
Mouse models demonstrate that schistosome infections shift host immunity away from
antiviral cytolytic T-helper (Th)-1 immune responses and towards a Th2-predominant
state, thereby prompting reactivation of latent viruses [43,44].
Studies have suggested that HIV-1 viral load set-point may be affected by host mucosal
inflammation [45,46]. In Ugandan HIV-1-serodiscordant couples, set-points were signifi-
cantly higher in those who reported genital ulcer disease in the six months prior to HIV-1
infection than in those without genital disease [45]. South African women who had high levels
of inflammatory genital cytokines before and 6 weeks after HIV-1 acquisition ultimately devel-
oped set-points that were significantly higher than those without genital inflammation [46].
Studies have shown that schistosomiasis also alters host mucosal immunity, and our study
demonstrates that schistosomiasis increases viral loads at the time of HIV-1 seroconversion.
Fig 3. Median log10 whole blood HIV-1 RNA levels in recent HIV-1 seroconverters with and without
schistosome infection. Summary plot depicting median and interquartile range of log10 of whole blood HIV-1 RNA
level in copies/mL as quantitated from dried blood spots in recent HIV-1 seroconverters with or without schistosome
infection. The median viral load was 4.4 [3.9–4.6] HIV-1 RNA log copies/mL in those with schistosome infection
versus 3.7 [3.2–4.3] among those without (p = 0.017 by Wilcoxon rank-sum test).
https://doi.org/10.1371/journal.pntd.0005968.g003
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An important future question, which we did not have power to answer, is whether the effect of
schistosomiasis on viral load at HIV-1 seroconversion differs by gender, which would further
implicate the genital mucosa as a critical mediator of the effect of schistosomiasis on HIV-1.
The single measurement of HIV-1 RNA level was likely to be reflective of the true viral load
set-point for the large majority of the recent HIV-1 seroconverters in our study. Had addi-
tional samples been available, it would have been ideal to confirm values for HIV-1 viral load
set-points in two separate samples collected between 6 weeks and 24 months after HIV sero-
conversion [15,25,26]. Acute HIV-1 seroconverters experience peak HIV-1 viremia a median
of 13 days after HIV-1 RNA becomes detectable, and the HIV antibody test becomes positive a
median of one day later [15]. These seroconverters would then be predicted to have a window
lasting approximately 17 days during which the HIV antibody test would be positive and the
HIV-1 RNA would not yet have reached a nadir or set-point [15]. Given the three-year HIV-
testing intervals in our study, 1.6% of participants (less than 1 of the 37 HIV-seroconverters)
would be predicted to have had a dried blood spot collected during this window. Indeed, only
one person in our study had a viral load greater than 5 log10 copies/mL, and that person was
schistosome-uninfected.
It is also unlikely that antiretroviral therapy use impacted our viral load analysis because we
limited our analysis to individuals who HIV-seroconverted in 2010. In 2010, antiretroviral
therapy was not yet widely available in the area and was only prescribed for individuals with
CD4+ T-cell counts < 200 cells/μL or to HIV-infected mothers between 28 weeks of gestation
and one week post-partum [23,24]. Only 17% of all HIV-infected pregnant mothers in Kisesa
received this three-month course of antiretroviral therapy in 2010 [24]. The two HIV-infected
women who delivered 5 and 6 months prior to dried blood spot collection had viral loads
above 4 log10 copies/mL, suggesting that even if they did receive antiretroviral therapy around
the time of delivery, they were not likely receiving antiretroviral therapy at the time of viral
load measurement. Further, our sensitivity analysis showed significant differences in median
viral loads even with removal of the two schistosome-uninfected individuals who had HIV-1
RNA levels less than 400 copies/mL and increases the robustness of our findings.
Because CAA testing cannot distinguish between schistosome species, we cannot determine
with certainty whether S. haematobium, S. mansoni, or both increase susceptibility to HIV
infection. It remains possible that our findings are driven by a small number of cases of S. hae-
matobium infection. This seems unlikely given that multiple epidemiologic surveys have
shown that the prevalence of S. mansoni is 20 times higher than S. haematobium in our popula-
tion. Due to our utilization of archived samples, our study was limited by the small blood
spot volume available and the lack of other samples for additional laboratory testing. We there-
fore relied on symptom report rather than laboratory confirmation of genital tract infections. A
strength of our study is that ample demographic, behavioral, and symptom-report data allowed
us to control at least partially for some of the other known HIV-1 risk factors. We were also
unable to test for other helminth infections, including Wuchereria bancrofti, which has been
shown to increase the risk of incident HIV infection in individuals in southern Tanzania [47].
In the district in northern Tanzania where we worked, it was recently determined that mass
drug administration for elimination of W. bancrofti is not required due to low prevalence [48].
The definitive study to determine causality will be an interventional trial showing that treating
schistosomiasis decreases incident HIV-1 infections and lowers viral load set-points.
In conclusion, we have demonstrated that chronic schistosome infection increases HIV-1
incidence in women and raises the HIV-1 viral load at the time of HIV-1-seroconversion. Pra-
ziquantel is an inexpensive, safe medication for schistosome infection [1]. Studies have shown
that mass therapy can decrease the community prevalence of schistosome infection and that it
may reverse urogenital tract pathology, particularly in younger individuals [49]. Robust
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prospective data to determine the effects of praziquantel treatment on tissue pathology in ado-
lescents and adults is lacking. Our findings suggest that trials are warranted to determine the
effectiveness of mass praziquantel treatment to decrease HIV-1 transmission and slow HIV-1
disease progression.
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